About Integrated BioTherapeutics
Integrated BioTherapeutics (IBT) is an R&D stage biotechnology company using an integrated multidisciplinary approach for discovery and development of anti-infective vaccines and therapeutics. Our product development focus is on emerging infectious diseases and biodefense targets.
Integrated BioTherapeutics, Inc. was founded in 2005 by Dr. M. Javad Aman, then a research scientist at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). The company was founded to specialize in two disease areas: Staphylococcus aureus bacterial infections (e.g. MRSA -public health) and Ebola and Marburg filoviruses (biodefense). Dr. Aman and co-owner and VP of Vaccine Development, Dr. Kelly Warfield, are recognized leaders in the field of vaccine development for filoviruses and inventors of IBT's virus-like particle (VLP) filovirus vaccine product currently in development under NIAID funding. Both Dr. Warfield and Dr. Aman were researchers at USAMRIID where they and their colleagues invented the filovirus VLP vaccine. Dr. Aman and Dr. Warfield also worked on several other vaccines while at USAMRIID, including S. aureus vaccine candidates.
Shortly after its founding, IBT licensed the development rights from the U.S. Army for several vaccine candidates for S. aureus that Dr. Aman had worked on at USAMRIID. In 2008, IBT (then a 6 person company) won a $22M advanced development cost-reimbursement contract with the National Institute for Allergy and Infectious Diseases (NIAID) to develop a multivalent pan-filovirus vaccine using the VLP technology platform. Since 2008, IBT has secured and managed over $35 M in grant and contract funding for nearly all of its product research efforts including multiple S. aureus vaccine candidates, therapeutics for staphylococcal enterotoxin, and a second generation filovirus vaccine product candidate. IBT won the Incubator Company of the Year award in 2008 for "Best Life Sciences Company". In 2009, the Tech Council of Maryland awarded IBT the "Emerging Company of the Year" for the state of Maryland.
In 2009, IBT founded a services business, IBT Bioservices, to leverage the experience of its team in antiviral and antibacterial product R&D. IBT Bioservices has served as the primary CRO resource for clients doing antiviral drug development, animal model testing, and antimicrobial drug screening among other things. Our services have generated data that helped our clients secure multimillion dollar development contracts. You can learn more about IBT Bioservices at: www.ibtbioservices.com or by clicking the services link above.